SCHEMBL7945106

SCHEMBL7945106

COc1ccc2oc(C(=O)Nc3ccc(F)c(CNc4cccnc4N)c3)cc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.47
AURKB Q96GD4 1/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
MAPT P10636 2/20 0.46
TP53 P04637 2/20 0.46
TSHR P16473 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
BACE1 P56817 2/20 0.46
RXFP1 Q9HBX9 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
TAS1R3 Q7RTX0 4/20 0.43
TAS1R1 Q7RTX1 4/20 0.43
KMT2A Q03164 3/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
BCAT1 P54687 1/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7939890 0.88 NPC1 (0.46) RAB9ANPC1MAPTTP53BACE1
SCHEMBL7941526 0.87 RAB9A (0.52) RAB9ANPC1MAPTTP53TSHR
SCHEMBL12301465 0.87 NPC1 (0.53) RAB9ANPC1MAPTTP53TSHR
SCHEMBL7932672 0.86 BACE1 (0.62) AURKAAURKBRAB9ANPC1MAPT
SCHEMBL7944993 0.86 HPGD (0.49) RAB9ANPC1MAPTTP53TSHR
SCHEMBL7942889 0.85 NPC1 (0.54) AURKAAURKBRAB9ANPC1SMN1; SMN2
SCHEMBL7945674 0.84 AURKA (0.61) AURKAAURKBRAB9ANPC1TP53
SCHEMBL7944850 0.83 BACE1 (0.56) AURKAAURKBBACE1
SCHEMBL7940789 0.81 BACE1 (0.53) AURKAAURKBRAB9AMAPTSMN1; SMN2
SCHEMBL7941927 0.81 POLB (0.46) RAB9ANPC1MAPTTP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 AURKA 3552/4885AURKB 2842/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.